Related Experiment Video

Updated: Aug 11, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica

M A Gonzalez-Gay1

  • 1Rheumatology Division, Hospital-Xeral Calde, Lugo, Spain. miguelaggay@hotmail.com

Arthritis Research
|April 12, 2001
PubMed

Insights

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are linked conditions in older adults. Genetic factors like HLA-DRB1*04 and others influence susceptibility, but more research is needed.

Area of Science:

  • Rheumatology
  • Immunogenetics
  • Epidemiology

Background:

  • Giant cell arteritis (GCA), also known as temporal arteritis, and polymyalgia rheumatica (PMR) are common inflammatory conditions affecting individuals over 50.
  • These two conditions are frequently observed together, suggesting shared underlying mechanisms.
  • While GCA is strongly associated with HLA-DRB1*04 alleles, the genetic susceptibility for isolated PMR appears to be population-dependent.

Purpose of the Study:

  • To review the current understanding of genetic factors influencing susceptibility to GCA and PMR.
  • To explore the roles of human leukocyte antigen (HLA) class II alleles, tumor necrosis factor (TNF), and specific gene polymorphisms in the pathogenesis of these conditions.

Main Methods:

  • Review of existing literature on the genetic associations of GCA and PMR.
  • Analysis of studies investigating HLA class II alleles, TNF, and polymorphisms in ICAM-1, RANTES, and IL-1 receptor antagonist genes.

Main Results:

  • A consistent association between GCA and HLA-DRB1*04 alleles has been reported.
  • Tumor necrosis factor (TNF) is implicated in the susceptibility to both GCA and PMR.
  • Gene polymorphisms in ICAM-1, RANTES, and IL-1 receptor antagonist may contribute to GCA and PMR pathogenesis in certain populations.

Conclusions:

  • Genetic factors, including HLA alleles and polymorphisms in inflammatory mediator genes, play a role in GCA and PMR susceptibility.
  • Further research is necessary to fully elucidate the complex genetic landscape underlying these related rheumatological conditions.

More Related Videos

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...